These are exciting times, with fresh news about research developments appearing every week.
Find out about the latest research news below and also visit our Breaking News in Research page.
British Science Week 2020
For this year’s British Science Week, the theme of which is “Our Diverse Planet”, we’d like to tell you about some exciting research we’ve funded.
Read more-
New guidance on the safety of medicine use in people with mitochondrial myopathies
13/02/2020Updated guidance on the medicines that should be avoided or used with caution in people with primary mitochondrial disease from the IMP
-
Quality of life study into Duchenne
05/02/2020Research is being carried out looking at the impact of Duchenne on family carers.
-
New publication gives insights into the discontinued DMD drug, ezutromid
31/01/2020The results from the MDUK-funded research project gives insight into the drugs, ezutromid
-
Update from the European Neuromuscular Centre
29/01/2020The ENMC is an international organisation that supports research for neuromuscular conditions and strives to facilitate communication among scientists and clinicians.
-
-
New study for Dysferlinopathy (LGMD2B/R2 or MM) is looking for participants
23/01/2020The second phase of an LGMD 2B study is looking for participants
-
-
IBM drug receives Fast Track designation
19/12/2019Orphazyme have announced that the U.S Food and Drug Administration (FDA) have granted the drug, arimoclomol, Fast Track designation.
-
Wave halts development of DMD drug
17/12/2019Wave Life Sciences have announced the disappointing news that the development of the drug suvodirsen for DMD has been discontinued.
-
Duchenne exon skipping drug approved by FDA
13/12/2019Sarepta’s exon skipping drug, VYONDYS 53™ (golodirsen) has been approved by the Food and Drug Administration (FDA). The FDA regulates drugs in the USA.